Todd Watanabe Biography and Net Worth

Mr Watanabe has been the president of Arcutis since 2016, and chief executive officer since 2017. Prior to joining Arcutis, he was co-founder and chief operating officer of Kanan Therapeutics, a cardiovascular drug development company, and before that, was vice president of strategy and corporate development at Kythera Biopharmaceuticals.

Mr Watanabe was an executive at Amgen, Inc. from 2005 to 2013, where he was involved in the development of Repatha^® for hyperlipidemia and Aimovig^® for migraine, and worked on the US marketing of Enbrel^® in both dermatology and rheumatology. Previously, he was an executive with Eli Lilly and Company, and an official in the US government. He was also a commissioned officer in the US Navy Reserves for 25 years. He formerly served on the board of Amunix Pharmaceuticals. Mr Watanabe earned his MA in national security studies, and his BA in international relations, both at Georgetown University.

What is Todd Watanabe's net worth?: The estimated net worth of Todd Watanabe is at least $23.04 million as of November 21st, 2025. Watanabe owns 793,838 shares of Arcutis Biotherapeutics stock worth more than $23,037,179 as of December 13th. This net worth estimate does not reflect any other assets that Watanabe may own. Additionally, Watanabe receives a salary of $1,010,000.00 as Insider at Arcutis Biotherapeutics. Learn More about Todd Watanabe's net worth.
How old is Todd Watanabe?: Watanabe is currently 56 years old. There are 6 older executives and no younger executives at Arcutis Biotherapeutics. Learn More on Todd Watanabe's age.
What is Todd Watanabe's salary?: As the Insider of Arcutis Biotherapeutics, Inc., Watanabe earns $1,010,000.00 per year. Learn More on Todd Watanabe's salary.
How do I contact Todd Watanabe?: The corporate mailing address for Watanabe and other Arcutis Biotherapeutics executives is 2945 TOWNSGATE ROAD SUITE 110, WESTLAKE VILLAGE CA, 91361. Arcutis Biotherapeutics can also be reached via phone at 805-418-5006 and via email at [email protected]. Learn More on Todd Watanabe's contact information.
Has Todd Watanabe been buying or selling shares of Arcutis Biotherapeutics?: During the past quarter, Todd Watanabe has sold $3,688,836.73 of Arcutis Biotherapeutics stock. Most recently, Todd Watanabe sold 48,945 shares of the business's stock in a transaction on Monday, November 24th. The shares were sold at an average price of $30.36, for a transaction totalling $1,485,970.20. Following the completion of the sale, the insider now directly owns 740,537 shares of the company's stock, valued at $22,482,703.32. Learn More on Todd Watanabe's trading history.
Who are Arcutis Biotherapeutics' active insiders?: Arcutis Biotherapeutics' insider roster includes Patrick Burnett (Insider), Scott Burrows (CFO), Bhaskar Chaudhuri (Director), Terrie Curran (Director), Larry Edwards (Insider), Patrick Heron (Director), Neha Krishnamohan (Director), Masaru Matsuda (General Counsel), David Topper (CFO), Patricia Turney (SVP), Latha Vairavan (CFO), Todd Watanabe (Insider), Todd Watanabe (CEO), and Howard Welgus (Director). Learn More on Arcutis Biotherapeutics' active insiders.
Are insiders buying or selling shares of Arcutis Biotherapeutics?: During the last year, Arcutis Biotherapeutics insiders bought shares 4 times. They purchased a total of 7,434 shares worth more than $99,276.66. During the last year, insiders at the sold shares 50 times. They sold a total of 552,442 shares worth more than $11,637,612.79. The most recent insider tranaction occured on December, 1st when insider Masaru Matsuda sold 1,657 shares worth more than $50,091.11. Insiders at Arcutis Biotherapeutics own 9.4% of the company. Learn More about insider trades at Arcutis Biotherapeutics.
Information on this page was last updated on 12/1/2025.

Todd Watanabe Insider Trading History at Arcutis Biotherapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/24/2025	Sell	48,945	$30.36	$1,485,970.20	740,537
11/21/2025	Sell	1,055	$30.00	$31,650.00	793,838
11/3/2025	Sell	11,547	$24.72	$285,441.84	794,893
10/28/2025	Sell	40,000	$25.03	$1,001,200.00	806,440
10/2/2025	Sell	20,739	$20.04	$415,609.56	846,440
10/1/2025	Sell	24,261	$19.33	$468,965.13	867,179
9/9/2025	Sell	504	$17.52	$8,830.08	891,440
9/8/2025	Sell	9,625	$17.54	$168,822.50	891,944
8/4/2025	Sell	11,547	$14.33	$165,468.51	901,569

Todd Watanabe Buying and Selling Activity at Arcutis Biotherapeutics

Arcutis Biotherapeutics Company Overview

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Today's Range

Now: $29.02

$28.30

$29.51

50 Day Range

MA: $25.27

$19.64

$31.20

2 Week Range

Now: $29.02

$11.13

$31.77

Volume

1,760,801 shs

Average Volume

2,323,730 shs

Market Capitalization

$3.55 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.69

Todd Watanabe Biography and Net Worth

What is Todd Watanabe's net worth?

How old is Todd Watanabe?

What is Todd Watanabe's salary?

How do I contact Todd Watanabe?

Has Todd Watanabe been buying or selling shares of Arcutis Biotherapeutics?

Who are Arcutis Biotherapeutics' active insiders?

Are insiders buying or selling shares of Arcutis Biotherapeutics?